



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https:// www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 41708

Title: Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: challenges of daily clinic practice.

Reviewer's code: 00112071

Reviewer's country: Australia

Science editor: Ruo-Yu Ma

Date sent for review: 2018-09-26

Date reviewed: 2018-10-03

Review time: 7 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

A comprehensive well written manuscript on selecting patient with pancreatic adenocarcinoma for genetic predisposition. Use of EUROPAC research criteria in this situation to review potential patients meeting these criteria in a consecutive patients in a

single tertiary referral centre and seeing the actual real world experience and reasons for only a small number being screened. As well as established benefits of genetic counselling and surveillance advances in developmental therapeutics mean that germline mutations are potentially druggable. Paper is appropriately supported by tables, figures and the references. The authors make some observations of the challenges of identification and some practice suggestions. Some discussion on on identification and early referral of patients before they deteriorate is present. A comment on appropriately resourcing of s genetic counselling services and access to genomics would be useful if teh actual numbers who could benefit from screening are referred. A table to compare the research based EUROPAC guidelines with the referenced clinical guidelines would be useful. Reference 6: author list is corrupted.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No